HER2 discordance between primary breast cancer and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis

Breast Cancer Research and Treatment

Volumn 129, Issue 3, 2011, Pages 659-674

  Houssami, Nehmat ^a   MacAskill, Petra ^a   Balleine, Rosemary L ^b   Bilous, Michael ^c   Pegram, Mark D ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Healthscope Pathology   (Australia)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2 HER2; Meta analysis; Metastasis; Test discordance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; BREAST CANCER; CANCER CLASSIFICATION; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LOCAL METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY CONTROL; REGIONAL METASTASIS; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS;

EID: 80052593511     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1632-x     Document Type: Review

References (60)

1. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
2. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
3. YJ Bang CE Van A Feyereislova, et al. 2010 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687 697 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO
4. JS Ross EA Slodkowska WF Symmans L Pusztai PM Ravdin GN Hortobagyi 2009 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320 368 19346299 10.1634/theoncologist. 2008-0230 1:CAS:528:DC%2BD1MXlvFOhtLw%3D
5. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
6. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
7. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D (Pubitemid 34111379)
8. MD Pegram A Lipton DF Hayes, et al. 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659 2671 9704716 1:CAS:528:DyaK1cXlsFCgurs%3D (Pubitemid 28363029)
9. MD Pegram T Pienkowski DW Northfelt, et al. 2004 Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 759 769 15150304 10.1093/jnci/djh133 1:CAS:528:DC%2BD2cXkt1Sqsbg%3D (Pubitemid 38771821)
10. J Hurley P Doliny I Reis, et al. 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 1831 1838 16549824 10.1200/JCO.2005.02.8886 1:CAS:528:DC%2BD28XkvVajt7k%3D (Pubitemid 46638980)
11. S Johnston J Pippen Jr X Pivot, et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 5538 5546 19786658 10.1200/JCO.2009.23.3734 1:CAS:528:DC%2BC3cXhtVWit7w%3D
12. L Harris H Fritsche R Mennel, et al. 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
13. M Dowsett AM Hanby R Laing R Walker HER National 2007 HER2 testing in the UK: consensus from a national consultation J Clin Pathol 60 685 689 17322344 10.1136/jcp.2006.044321 (Pubitemid 46975226)
14. RW Carlson DC Allred BO Anderson, et al. 2009 Breast cancer. Clinical practice guidelines in oncology J Natl Compr Cancer Netw 7 122 192 1:CAS:528:DC%2BD1MXjs1Oktbg%3D
15. M Tanner P Jarvinen J Isola 2001 Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer Cancer Res 61 5345 5348 11454672 1:CAS:528:DC%2BD3MXlsVChsrw%3D (Pubitemid 32694907)
16. F Cardoso A Di Leo D Larsimont, et al. 2001 Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes Ann Oncol 12 615 620 11432618 10.1023/A:1011182524684 1:STN:280:DC%2BD38%2Fhs1CjtA%3D%3D (Pubitemid 32519912)
17. EE Lower E Glass R Blau S Harman 2009 HER-2/neu expression in primary and metastatic breast cancer Breast Cancer Res Treat 113 301 306 18273700 10.1007/s10549-008-9931-6 1:CAS:528:DC%2BD1MXhsVKntA%3D%3D
18. L Pusztai G Viale C Kelly C Hudis 2010 Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 1164 1168 21041379 10.1634/theoncologist.2010-0059
19. E Amir M Clemons 2009 Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10 933 935 19796747 10.1016/S1470-2045(09)70295-5
20. K Aoyama T Kamio T Nishikawa S Kameoka 2010 A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes Jpn J Clin Oncol 40 613 619 20202990 10.1093/jjco/hyq019
21. C Shimizu T Fukutomi H Tsuda, et al. 2000 c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues J Surg Oncol 73 17 20 10649273 10.1002/(SICI)1096-9098(200001)73:1<17::AID- JSO5>3.0.CO;2-2 1:CAS:528:DC%2BD3cXhtFaru7c%3D (Pubitemid 30067528)
22. S Masood MM Bui 2000 Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 259 265 10945565 1:CAS:528:DC%2BD3cXmtVeqtLg%3D (Pubitemid 30620800)
23. D Gancberg A Di Leo F Cardoso, et al. 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 1036 1043 12176781 10.1093/annonc/mdf252 1:STN:280: DC%2BD38vitFWgtQ%3D%3D
24. S Tsutsui S Ohno S Murakami A Kataoka J Kinoshita Y Hachitanda 2002 EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer Eur J Surg Oncol 28 383 387 12099646 1:STN:280:DC%2BD38zlslShug%3D%3D
25. A Vincent-Salomon M Jouve P Genin, et al. 2002 HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2169 2173 12001113 10.1002/cncr.10456 1:CAS:528:DC%2BD38Xjs12gtLw%3D (Pubitemid 34411973)
26. Y Sekido S Umemura S Takekoshi, et al. 2003 Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation Int J Oncol 22 1225 1232 12738987 1:CAS:528:DC%2BD3sXksV2nsrc%3D
27. SM Edgerton D Moore D Merkel AD Thor 2003 erbB-2 (HER-2) and breast cancer progression Appl Immunohistochem Mol Morphol 11 214 221 12966347 1:CAS:528:DC%2BD3sXntFSnsbY%3D (Pubitemid 37082057)
28. P Regitnig W Schippinger M Lindbauer H Samonigg SF Lax 2004 Change of HER-2/neu status in a subset of distant metastases from breast carcinomas J Pathol 203 918 926 15258994 10.1002/path.1592 1:CAS:528:DC%2BD2cXmvVajsLk%3D (Pubitemid 39089280)
29. J Carlsson H Nordgren J Sjöström, et al. 2004 HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 2344 2348 15150568 1:CAS:528: DC%2BD2cXks1aht7k%3D (Pubitemid 38961898)
30. J Zidan I Dashkovsky C Stayerman W Basher C Cozacov A Hadary 2005 Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease Br J Cancer 93 552 556 16106267 10.1038/sj.bjc.6602738 1:CAS:528:DC%2BD2MXpsFalur0%3D (Pubitemid 43079998)
31. M Azam A Qureshi S Mansoor 2009 Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma J Pak Med Assoc 59 736 740 20361669
32. SJ Aitken JS Thomas SP Langdon DJ Harrison D Faratian 2010 Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Ann Oncol 21 1254 1261 19858088 10.1093/annonc/mdp427 1:STN:280:DC%2BC3czlvF2ktQ%3D%3D
33. MP Santiago A Vazquez-Boquete B Fernandez, et al. 2009 Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis Histol Histopathol 24 675 682 19337966 1:CAS:528:DC%2BD1MXltFCnt7s%3D
34. PK Idirisinghe AA Thike PY Cheok, et al. 2010 Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance Am J Clin Pathol 133 416 429 20154280 10.1309/AJCPJ57FLLJRXKPV
35. R Simon A Nocito T Hubscher, et al. 2001 Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 1141 1146 11481385 10.1093/jnci/93.15.1141 1:CAS:528: DC%2BD3MXmtVGqsLc%3D (Pubitemid 32780965)
36. V Guarneri S Giovannelli G Ficarra, et al. 2008 Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 838 844 18650259 10.1634/theoncologist.2008-0048 1:CAS:528:DC%2BD1cXhtF2qs7vP
37. A Santinelli E Pisa D Stramazzotti G Fabris 2008 HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy Int J Cancer 122 999 1004 17973263 10.1002/ijc.23051 1:CAS:528: DC%2BD1cXhslGhtb0%3D (Pubitemid 351213996)
38. Y Gong DJ Booser N Sneige 2005 Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 103 1763 1769 15786420 10.1002/cncr.20987 1:CAS:528:DC%2BD2MXktFGnsbw%3D (Pubitemid 40563246)
39. C Tapia S Savic U Wagner, et al. 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 R31 17511881 10.1186/bcr1676 (Pubitemid 350215176)
40. EY Cho JJ Han YL Choi KM Kim YL Oh 2008 Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study J Korean Med Sci 23 1053 1061 19119452 10.3346/jkms.2008.23.6.1053
41. C Simmons N Miller W Geddie, et al. 2009 Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 1499 1504 19299408 10.1093/annonc/mdp028 1:STN:280: DC%2BD1MrnsVaqtg%3D%3D
42. R Xu MA Perle G Inghirami W Chan Y Delgado H Feiner 2002 Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material Mod Pathol 15 116 124 11850540 10.1038/modpathol. 3880503 (Pubitemid 34171321)
43. KC Lear-Kaul HR Yoon BK Kleinschmidt-DeMasters L McGavran M Singh 2003 Her-2/neu status in breast cancer metastases to the central nervous system Arch Pathol Lab Med 127 1451 1457 14567724 1:CAS:528:DC%2BD3sXpsVCru70%3D (Pubitemid 37370391)
44. GA Niehans TP Singleton D Dykoski DT Kiang 1993 Stability of HER-2/neu expression over time and at multiple metastatic sites J Natl Cancer Inst 85 1230 1235 8101229 10.1093/jnci/85.15.1230 1:STN:280:DyaK3szitlWntw%3D%3D (Pubitemid 23223529)
45. LA Krogerus M Leivonen 2001 HER-2/neu oncogene expression in advanced breast cancer Cancer Detect Prev 25 1 7 11270416 1:CAS:528:DC%2BD3MXltFalsbc%3D
46. MR D'Andrea MR Limiti M Bari, et al. 2007 Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis Breast Cancer Res Treat 101 279 284 16835704 10.1007/s10549-006-9300-2 (Pubitemid 46169881)
47. C Bozzetti N Personeni R Nizzoli, et al. 2003 HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma Cancer 99 310 315 14579298 10.1002/cncr.11731 1:CAS:528:DC%2BD3sXovFymtL8%3D (Pubitemid 37248379)
48. RJ Broom PA Tang C Simmons, et al. 2009 Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 1557 1562 19443366
49. S Meng D Tripathy S Shete, et al. 2004 HER-2 gene amplification can be acquired as breast cancer progresses Proc Natl Acad Sci USA 101 9393 9398 15194824 10.1073/pnas.0402993101 1:CAS:528:DC%2BD2cXltlKjsL4%3D (Pubitemid 38812885)
50. L Strien M Leidenius K von Smitten P Heikkila 2010 Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells Pathol Res Pract 206 253 258 20138441 10.1016/j.prp.2009.12.006
51. LM McShane DG Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 1180 1184 16106022 10.1093/jnci/dji237 1:CAS:528:DC%2BD2MXpsVaks7s%3D (Pubitemid 41258223)
52. MS Pepe Z Feng H Janes PM Bossuyt JD Potter 2008 Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design J Natl Cancer Inst 100 1432 1438 18840817 10.1093/jnci/djn326 1:CAS:528:DC%2BD1cXht1Oisb7P
53. MF Press RS Finn D Cameron, et al. 2008 HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer Clin Cancer Res 14 7861 7870 19047115 10.1158/1078-0432.CCR-08-1056 1:CAS:528:DC%2BD1cXhsVegt77P
54. M Bilous M Dowsett W Hanna, et al. 2003 Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173 182 12591971 10.1097/01.MP.0000052102.90815.82 (Pubitemid 36245750)
55. M Dowsett J Bartlett IO Ellis, et al. 2003 Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 418 423 12635131 10.1002/path.1313 1:CAS:528:DC%2BD3sXlt1Sgtrc%3D (Pubitemid 36411217)
56. M Bilous A Morey J Armes M Cummings G Francis 2006 Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry Pathology 38 120 124 16581651 10.1080/00313020600561518 1:CAS:528:DC%2BD28XjtVKqt7o%3D
57. V van de Vijver M Bilous W Hanna, et al. 2007 Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study Breast Cancer Res 9 R68 17922920 10.1186/bcr1776
58. National Collaborating Centre for Cancer (developed for National Institute for Health and Clinical Excellence (NICE) clinical guideline 81). Advanced breast cancer: diagnosis and treatment 2009. Website: www.nice.org.uk/nicemedia/live/11778/43305/43305.pdf
59. J Sjöström J Collan K von Boguslawski, et al. 2002 C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer Eur J Cancer 38 535 542 11872346 10.1016/S0959-8049(01)00403-8 (Pubitemid 34185393)
60. MJ Piccart A Di Leo M Beauduin, et al. 2001 Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 19 3103 3110 11408507 1:CAS:528:DC%2BD3MXltFektLo%3D (Pubitemid 32565448)